At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 276 enrolled
Drug / intervention
Depemokimab (GSK3511294) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-1 (depemokimAb iN CHrOnic Rhinosinusitis)
In Brief
A Phase 3 clinical trial evaluating Depemokimab (GSK3511294) and Placebo for Nasal Polyps. Completed, enrolled 276 participants across 105 sites in 11 countries.
Detailed Summary
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasal Polyps
CountriesArgentina, Belgium, Canada, China, France, Germany, Japan, Netherlands, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartApr 2022
Primary CompletionJul 2024
Study CompletionAug 2024
TodayJul 2026
First PostedMar 10, 2022
Enrollment StartApr 22, 2022
Primary CompletionJul 30, 2024
Study CompletionAug 27, 2024
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 4.3 years ago
Interventions
Depemokimab (GSK3511294)biological
Depemokimab (GSK3511294) was administered using a pre- filled syringe.
Placebodrug
Placebo was administered as normal saline using a pre-filled syringe.